JPMorgan analyst Gary Taylor raised his price target for UnitedHealth to $266 following yesterday's Q1 results. The company continues to exceed bullish expectations and its upside in Q1 bodes well for the remainder of the year, Taylor tells investors in a post-earnings research note. The analyst keeps an Overweight rating on the shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here